AIM ImmunoTech Inc. (AIM)
| Market Cap | 8.82M |
| Revenue (ttm) | 190,000 |
| Net Income (ttm) | -23.93M |
| Shares Out | 63.78M |
| EPS (ttm) | -0.46 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 349,672 |
| Open | 0.142 |
| Previous Close | 0.143 |
| Day's Range | 0.138 - 0.144 |
| 52-Week Range | 0.120 - 0.620 |
| Beta | -0.30 |
| Analysts | Strong Buy |
| Price Target | 2.75 (+1,888.43%) |
| Earnings Date | Apr 1, 2025 |
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well ... [Read more]
Financial Performance
In 2023, AIM ImmunoTech's revenue was $202,000, an increase of 43.26% compared to the previous year's $141,000. Losses were -$28.96 million, 48.9% more than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for AIM stock is "Strong Buy." The 12-month stock price forecast is $2.75, which is an increase of 1,888.43% from the latest price.
News
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod) ...
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Registration ...
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune ...
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the Ef...
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
OCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (t...
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elec...
AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders...
Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board
Vote “ FOR ” All Four Kellner Group Nominees Today on Gold Card for Urgently Needed Change
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders...
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has grant...
Kellner Group Announces Support from Another Former AIM Senior Executive
NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectivel...
AIM's Clinical Strategy Under Incumbent Board Has Totally Failed
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectivel...
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has recomme...
Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected
Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) ...
AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment
Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card
ISS Notes Need for Significant Board Change at AIM Due to Clinical Failure and Lack of Transparency According to ISS – “ There is no question that for shareholders to have any hope of not losing 100 p...
ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M.
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has...
AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation highlighting why shareholders should NOT elect the four director candidates ...
AIM ImmunoTech Refutes Activist Group's False and Misleading Claims
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued the following statement refuting the false and misleading claims recently made by a group o...
AIM ImmunoTech Announces Cash Conservation Plan
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Compensation Committee of the Company's Board of Directors (the “Board”) has es...
AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders
OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation in connection with its upcoming 2024 Annual Meeting of Stockholders the (“An...
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer Center's ...
AIM ImmunoTech Inc. (AIM) Q3 2024 Earnings Call Transcript
AIM ImmunoTech Inc. (NYSE:AIM) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants Thomas Equels - CEO Christopher McAleer - Scientific Officer Conference Call Particip...